|
Fototerapia y Psoriasis
La psoriasis es caracterizada por
parches de piel roja, inflamada. La psoriasis se desarrolla porque las capas
exteriores de las células de la piel se reproducen muy rápidamente. La psoriasis
causa dolor y picazón, movimiento limitado, y tensión. Estudios recientes
muestran que la psoriasis puede ser un desorden inmune en el cual las células T
se comportan de manera anormal. El tratamiento de luz Ultravioleta para
psoriasis, también conocido como fototerapia Ultravioleta Fototerapia, expone
las células T, causándoles que mueran. De esta manera, la luz de fototerapia
reduce la inflamación, y disminuye la velocidad del rango de producción de
células de la piel. Durante la fase de aclaramiento, los tratamientos de
fototerapia Ultravioleta son de 3 a 5 veces por semana con aumento de
exposiciones. El tratamiento de luz Ultravioleta para psoriasis ayuda a limpiar
o mejorar la psoriasis en la mayoría de las personas. El Doctor le puede recetar
luz Ultravioleta A, Ultravioleta B o Ultravioleta B De banda angosta.
- before and after -
Vea la investigación de fototerapia Ultravioleta
para psoriasis.
tratemiento para
fototerapia
Equipo de Fototerapia
 Nuestro
equipo de fototerapia ha sido muy estudiado y ha sido probado que es altamente
efectivo para el tratamiento de la psoriasis. Los tratamientos de psoriasis en
el hogar o en la oficina de su doctor es una decisión entre usted y su doctor.
Las unidades de
Fototerapia en el Hogar son generalmente rembolsadas
por el seguro. La unidad de fototerapia apropiada está basada en el tamaño del
área afectada. Nosotros tenemos paneles de luz de 6-pies y 2-pies
Panosol-II,
una cabina plegable de tamaño completo
Foldalite-III cuando la psoriasis cubre mucha área del cuerpo. El modelo de
mano
Dermalight-80 es ideal para áreas más pequeñas de soriasis y para
tratamiento de psoriasis para el cuello cabelludo.
|
#1 Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy. Lim C. The Australasian Journal Of Dermatology [Australas J Dermatol], 2006 Feb; Vol. 47 (1), pp. 37-40; PMID: 16405481;
|
| ABSTRACT:
Psoriasis is a chronic fluctuating dermatosis with demonstrable impact on patients' quality of life. Our aim was to investigate if narrowband UVB phototherapy administered to psoriatic patients in a standardized manner leads to an improvement in patients' perceived quality of life. A total of 138 patients with psoriasis were recruited from referrals to the Skin and Cancer Foundation, Australia between January 1998 and September 2002. Patients had psoriasis inadequately controlled by topical therapies alone and no contraindications to the use of phototherapy. Patients completed a pre- and post-therapy questionnaire on quality of life parameters. The differences in mean and standard deviation of quality of life parameters were measured using a paired sample t-test based on pre- and post-phototherapy questionnaires. Ninety patients were included in the study. Forty-eight patients were excluded as they had not completed post-phototherapy questionnaires. The course of narrowband UVB phototherapy was found to significantly improve quality of life in psoriasis patients (P <or= 0.005). We conclude that narrowband UVB phototherapy improves quality of life in patients with psoriasis. |
 |
|
#2 Cost-effectiveness of moderate-to-severe psoriasis treatment. Miller DW. Expert Opinion On Pharmacotherapy
[Expert Opin Pharmacother], 2006 Feb; Vol. 7 (2), pp. 157-67; PMID: 16433581. |
| Psoriasis is a common, chronic inflammatory disease that can cause as much disability as cancer, diabetes or other major medical illnesses. Traditional therapies for treating moderate-to-severe psoriasis include phototherapy, methotrexate, oral retinoids and ciclosporin. New biological treatments provide further therapeutic options, but add to the already considerable cost of managing psoriasis. Expert panels have published guidelines for the use of biological agents in managing moderate-to-severe psoriasis; however, few if any of these guidelines appropriately consider the cost-effectiveness of treatment options. When considering cost-effectiveness in addition to safety and efficacy, ultraviolet Type B phototherapy seems to be the best first-line agent for the control of moderate-to-severe psoriasis, despite a small potential for
cumulative toxicity. The biologics should be considered as second-line agents alongside the traditional systemic treatments when phototherapy proves to be ineffective or is otherwise contraindicated, such as in patients with psoriatic arthritis |
|
